Telix Pharmaceuticals Stock Jumps 15% After Earnings. Here’s What Gozellix-Driven Growth Means for 2026

2026-03-19 04:08:58

Telix Pharmaceuticals (TLX) shares surged nearly 15% after reporting strong 2025 results, including $804 million in revenue, and providing upbeat 2026 guidance of $950-$970 million, driven by products like Gozellix. Despite profitability remaining modest due to increased investments and ongoing legal challenges, analysts see significant upside with a mean price target of $30.84 against the current $7.69. The company’s future performance hinges on meeting revenue targets, advancing its pipeline, and resolving legal and financing uncertainties.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.